This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most ...

As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.

This panel brings together leading researchers to explore how health economics can inform policy design in the context of the climate crisis. Rather than proposing new evaluative paradigms, the ...

In our latest insight, we reflect on what we’re seeing in the region, from Saudi Arabia’s Vision 2030 to the UAE’s push for innovation and value in healthcare.

Next-generation sequencing (NGS) generates comprehensive and actionable information on molecular tumour profiles. But despite recommendations for the use of NGS in lung cancer, and support for its ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and ...

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted ...

Our Board of Trustees and advisory committees are essential to guiding our work, maintaining the quality and independence of our research programme and our publications, and ensuring we align with our ...

The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using a multi-criteria decision ...

In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions. Real-world evidence (RWE) can enable ...

New antibiotics are urgently needed, but their development is hindered by market failure. A 'volume-delinked model' subscription approach has been suggested to overcome this market failure, providing ...

Shortages have been observed across a range of therapeutic areas, particularly in the off-patent generic and biosimilar markets. Optimal policy design and decision-making require an understanding of ...